Clinical trial NCT00678171: A Pilot Study to Evaluate an Osteogenic Protein 1 (OP-1) Putty Spinal System and an Autograft Spinal System
Official title: A Pilot Study to Evaluate an OP-1 Putty Spinal System and an Autograft Spinal System in Patients Requiring Transforaminal Lumbar Interbody Fusion of the Spine
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Degenerative Disc Disease
Keywords: Degenerative Disc Disease
Lead sponsor: Olympus Biotech Corporation
Sponsor class: INDUSTRY
First posted: 2008-05-15
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: This study will explore the use of recombinant OP-1 in conjunction with surgical treatment of single-level TLIF of the lumbar spine.

Detailed description: This pilot study is a randomized, multi-center, prospective, controlled study of the efficacy and safety of OP-1 Putty Spinal System in patients requiring a single level transforaminal interbody fusion of the lumbar spine (TLIF).

Eligibility criteria: Inclusion Criteria:

1. The patient is willing and able to understand, sign and date the study-specific, Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved patient informed consent and applicable privacy regulations.
2. The patient has a documented diagnosis of DDD with up to Grade I spondylolisthesis demonstrated by radiographic imaging (by plain film/discography within 12 weeks of surgery and/or computed tomography (CT scan/magnetic resonance imaging \[MRI\].
3. The patient requires single level lumbar fusion (L2 to S1)

Exclusion Criteria:

1. The patient has a history of previous surgery in the lumbar spine with or without attempted fusion {Note: a history of lumbar decompression surgery is permitted}.
2. The patient has Grade II, Grade III or Grade IV spondylolisthesis.
3. The patient has gross spinal instability measured on flexion/extension radiographs of \>25% translation of the vertebrae, or ≥20 degrees of angular motion or has significant (\>10%) scoliosis.
4. The patient is receiving treatment (before, during or after surgery) with a drug that interferes with bone metabolism or is being treated with a bone growth stimulator.
5. The patient has been treated in the last 6 months with radiation, chemotherapy, immunosuppression or systemic corticosteroids.
6. The patient has a history of, or has any malignancy or spinal tumor of any type, with the exception of a history of a treated basal or squamous cell carcinoma.
7. The patient is morbidly obese (defined as body mass index \[BMI\] \> 35).
8. The patient currently uses tobacco products, within 3 weeks prior to time of treatment.
9. The patient is known to require at the time of treatment, additional surgery to the lumbar spinal region within the next 6 months or has symptomatic multilevel degenerative disease requiring possible instrumented fusion of more than one level.
10. The patient has previously been treated with or exposed to any Bone Morphogenetic Proteins (BMPs).
11. The patient is contraindicated for iliac crest autografting in that the Investigator believes the patient would be unable to provide sufficient quantity or adequate quality autograft (e.g., osteoporosis as defined by this protocol) from a unilateral iliac crest harvest.
12. The patient has a previous diagnosis of Paget's disease, osteomalacia or any other endocrine or metabolic bone disease that affects osteogenesis.
13. The patient has a documented history of osteoporosis or has a risk of osteoporosis as defined by an Osteoporosis Risk Assessment Instrument (ORAI) score of ≥ 9 and a DEXA Scan T score of ≥-2.5 standard deviations below the normal range within one year of enrollment.

Primary outcomes:
measure: Pain and function as measured by an Oswestry Disability Index, no revisions, removals or supplemental fixations, fusion success, defined as radiographic evidence of fusion, maintenance or improvement in lower extremity neurologic function
timeFrame: 12 and 24 months post intervention
Secondary outcomes:
measure: Quality of life determinations (SF-36), pain assessments (VAS), work status and assessment of additional radiographic parameters
timeFrame: 12 and 24 months post intervention
Other outcomes:
Locations:
city: Los Angeles
country: United States
state: California
city: San Diego
country: United States
state: California
city: Durango
country: United States
state: Colorado
city: Boston
country: United States
state: Massachusetts
city: Southfield
country: United States
state: Michigan
city: Minneapolis
country: United States
state: Minnesota
city: Omaha
country: United States
state: Nebraska
city: Charlotte
country: United States
state: North Carolina
city: Philadelphia
country: United States
state: Pennsylvania
city: Temple
country: United States
state: Texas
Study officials:
References: